Surface Oncology Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
01 avr. 2022 16h43 HE
|
Surface Oncology, Inc.
CAMBRIDGE, Mass., April 01, 2022 (GLOBE NEWSWIRE) -- Surface Oncology, Inc. (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...
Surface Oncology Achieves $30 Million Milestone with First Patient Dosed in GlaxoSmithKline Phase 1 Study
31 mars 2022 07h30 HE
|
Surface Oncology, Inc.
CAMBRIDGE, Mass., March 31, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...
Surface Oncology Appoints Theresa Boni as General Counsel
15 mars 2022 07h30 HE
|
Surface Oncology, Inc.
CAMBRIDGE, Mass., March 15, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...
Surface Oncology Reports Financial Results and Corporate Highlights for Fourth Quarter and Full Year 2021
02 mars 2022 07h10 HE
|
Surface Oncology, Inc.
Continued progress advancing next-generation antibody portfolio, with ongoing clinical trials evaluating the broad potential of SRF388 and SRF617 across multiple tumor types Company continues...
Surface Oncology to Participate in Novel Immuno-Oncology Panel at Cowen’s 42nd Annual Health Care Conference
28 févr. 2022 16h30 HE
|
Surface Oncology, Inc.
CAMBRIDGE, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...
Surface Oncology to Participate in Citi's 2022 Virtual Immuno-Oncology Summit
10 févr. 2022 07h00 HE
|
Surface Oncology, Inc.
CAMBRIDGE, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...
Surface Oncology Appoints Denice Torres as Chair of the Board of Directors
15 déc. 2021 07h05 HE
|
Surface Oncology, Inc.
Biopharma veteran Ben Hickey appointed to Board of Directors Lisa McGrath promoted to chief people officer; Shannon Devens promoted to senior vice president, development operations CAMBRIDGE, Mass.,...
Surface Oncology Presents Promising Clinical Data on SRF617 at the European Society for Medical Oncology Immuno-Oncology Congress (ESMO-IO) 2021
06 déc. 2021 09h30 HE
|
Surface Oncology, Inc.
CAMBRIDGE, Mass., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...
Surface Oncology Named a 2021 Top Place to Work by the Boston Globe
03 déc. 2021 07h00 HE
|
Surface Oncology, Inc.
CAMBRIDGE, Mass., Dec. 03, 2021 (GLOBE NEWSWIRE) -- Surface Oncology, a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment,...
Surface Oncology to Present New Clinical Data from Ongoing SRF617 Phase 1 Trial at the European Society for Medical Oncology Immuno-Oncology Congress (ESMO-IO) 2021
02 déc. 2021 07h00 HE
|
Surface Oncology, Inc.
CAMBRIDGE, Mass., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...